Evoke Begin Period Cash Flow vs Change In Working Capital Analysis
| EVOK Stock | USD 4.89 0.01 0.20% |
Evoke Pharma financial indicator trend analysis is much more than just examining Evoke Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Evoke Pharma is a good investment. Please check the relationship between Evoke Pharma Begin Period Cash Flow and its Change In Working Capital accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.
Begin Period Cash Flow vs Change In Working Capital
Begin Period Cash Flow vs Change In Working Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Evoke Pharma Begin Period Cash Flow account and Change In Working Capital. At this time, the significance of the direction appears to have no relationship.
The correlation between Evoke Pharma's Begin Period Cash Flow and Change In Working Capital is 0.06. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Change In Working Capital in the same time period over historical financial statements of Evoke Pharma, assuming nothing else is changed. The correlation between historical values of Evoke Pharma's Begin Period Cash Flow and Change In Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Evoke Pharma are associated (or correlated) with its Change In Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Working Capital has no effect on the direction of Begin Period Cash Flow i.e., Evoke Pharma's Begin Period Cash Flow and Change In Working Capital go up and down completely randomly.
Correlation Coefficient | 0.06 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Change In Working Capital
The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.Most indicators from Evoke Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Evoke Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.Selling General Administrative is expected to rise to about 11.6 M this year, although the value of Issuance Of Capital Stock will most likely fall to 0.00.
Evoke Pharma fundamental ratios Correlations
Click cells to compare fundamentals
Evoke Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Evoke Pharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 6.4M | 9.4M | 10.6M | 11.9M | 7.1M | 10.1M | |
| Other Current Liab | 1.9M | 6.0M | 506.9K | 528.1K | (3.7M) | (3.5M) | |
| Total Current Liabilities | 2.0M | 7.5M | 1.4M | 1.7M | 3.0M | 2.3M | |
| Total Stockholder Equity | 4.4M | (3.2M) | 3.6M | 4.1M | (2.6M) | (2.5M) | |
| Net Debt | (5.5M) | (2.8M) | (4.1M) | (4.7M) | 260.6K | 273.6K | |
| Retained Earnings | (85.7M) | (98.9M) | (107.4M) | (115.6M) | (123.4M) | (117.3M) | |
| Accounts Payable | 1.0M | 1.3M | 874.0K | 868.3K | 1.7M | 1.3M | |
| Cash | 5.7M | 8.1M | 9.1M | 9.8M | 4.7M | 6.6M | |
| Cash And Short Term Investments | 5.7M | 8.1M | 9.1M | 9.8M | 4.7M | 6.6M | |
| Common Stock Total Equity | 1.5K | 1.7K | 2.4K | 2.7K | 3.1K | 3.2K | |
| Common Stock Shares Outstanding | 1.9M | 177.0K | 223.5K | 262.0K | 278.6K | 264.7K | |
| Liabilities And Stockholders Equity | 6.4M | 9.4M | 10.6M | 11.9M | 7.1M | 10.1M | |
| Non Current Liabilities Total | 138.5K | 5.1M | 5.6M | 6.1M | 6.6M | 4.8M | |
| Other Current Assets | 581.7K | 952.1K | 935.3K | 964.5K | 932.6K | 570.4K | |
| Other Stockholder Equity | 90.1M | 95.7M | 111.0M | 119.7M | 120.9M | 75.9M | |
| Total Liab | 2.0M | 12.6M | 7.0M | 7.8M | 9.6M | 6.5M | |
| Total Current Assets | 6.2M | 9.3M | 10.6M | 11.7M | 6.8M | 10.0M | |
| Common Stock | 2.4K | 2.7K | 3.3K | 334.0 | 384.1 | 364.89 | |
| Net Tangible Assets | 4.4M | (3.2M) | 3.6M | 4.1M | 3.7M | 4.2M | |
| Non Current Assets Total | 150.1K | 153.3K | 12.4K | 129.1K | 241.6K | 253.7K | |
| Retained Earnings Total Equity | (71.0M) | (78.6M) | (85.7M) | (98.9M) | (89.0M) | (93.4M) | |
| Capital Surpluse | 73.2M | 82.6M | 90.1M | 95.7M | 110.0M | 74.9M | |
| Net Invested Capital | 4.4M | 1.9M | 8.6M | 9.1M | 2.4M | 2.3M | |
| Net Working Capital | 4.2M | 1.7M | 9.2M | 10.1M | 3.8M | 6.1M | |
| Capital Stock | 2.4K | 2.7K | 3.3K | 334.0 | 300.6 | 285.57 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evoke Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Evoke Stock please use our How to buy in Evoke Stock guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evoke Pharma. If investors know Evoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evoke Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.13) | Revenue Per Share 7.792 | Quarterly Revenue Growth 0.698 | Return On Assets (0.34) | Return On Equity (3.50) |
The market value of Evoke Pharma is measured differently than its book value, which is the value of Evoke that is recorded on the company's balance sheet. Investors also form their own opinion of Evoke Pharma's value that differs from its market value or its book value, called intrinsic value, which is Evoke Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evoke Pharma's market value can be influenced by many factors that don't directly affect Evoke Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evoke Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evoke Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evoke Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.